Contineum Therapeutics, Inc. Class A Common Stock beat EPS estimates 56% of the time across 9 reported quarters (5 beats, 4 misses), averaging +1.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.46 | $-0.40 | +13.0% | Beat | |
| Q1 FY26 | $-0.55 | $-0.39 | +29.1% | Beat | |
| Q4 FY25 | $-0.50 | $-0.49 | +2.0% | Beat | |
| Q3 FY25 | $-0.58 | $-0.45 | +22.4% | Beat | |
| Q2 FY25 | $-0.56 | $-0.62 | -10.7% | Miss | |
| Q1 FY25 | $-0.56 | $-0.62 | -10.7% | Miss | |
| Q4 FY24 | $-0.44 | $-0.56 | -27.3% | Miss | |
| Q3 FY24 | $-0.41 | $-0.40 | +2.4% | Beat | |
| Q2 FY24 | $-0.37 | $-0.39 | -5.4% | Miss | |
| Q1 FY24 | not reported | $-3.55 | not reported | not reported |
Back to CTNM overview · CTNM holders · CTNM KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.